Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction

Laboratory Investigation

Volumn 90, Issue 9, 2010, Pages 1365-1372

  Mohammad, Ghulam ^a   Kowluru, Renu A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; GELATINASE A; SMALL INTERFERING RNA; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; GLUCOSE; MANGANESE SUPEROXIDE DISMUTASE; MATRIX METALLOPROTEINASE 14; SUPEROXIDE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CAPILLARY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA; RETINA CAPILLARY; ANIMAL; BOVINAE; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PATHOLOGY; RETINA DISEASE;

ANIMALS; APOPTOSIS; CAPILLARIES; CATTLE; CYTOCHROMES C; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; GLUCOSE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MICE; MITOCHONDRIA; RETINA; RETINAL DISEASES; SUPEROXIDE DISMUTASE; SUPEROXIDES; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 77956238386     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.89     Document Type: Article

References (35)

1. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996;97:2883-2890.
2. Kern TS, Tang J, Mizutani M, et al. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 2000;41: 3972-3978.
3. Barber AJ, Lieth E, Khin SA, et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998;102:783-791.
4. Behl Y, Krothapalli P, Desta T, et al. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol 2008;172:1411-1418.
5. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625.
6. Hammes HP. Pathophysiological mechanisms of diabetic angiopathy. J Diabetes Complicat 2003;17:16-19.
7. Kowluru RA, Kern TS, Engerman RL, et al. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Diabetes 1996;45:1233-1237.
8. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001;50:1938-1942.
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
10. Kanwar M, Chan PS, Kern TS, et al. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest Ophthalmol Vis Sci 2007;48:3805-3811.
11. Kowluru RA, Abbas SN. Diabetes-induced mitochondrial dysfunction in the retina. Inves Ophthalmol Vis Sci 2003;44:5327-5334.
12. Kowluru RA. Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid Redox Signal 2005;7:1581-1587.
13. Kowluru RA, Atasi L, Ho YS. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2006;47:1594-1599.
14. Kowluru RA, Kowluru V, Ho YS, et al. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetesinduced oxidative stress. Free Rad Biol Med 2006;41:1191-1196.
15. Kanwar M, Kowluru RA. Role of glyceraldehyde 3-phosphate dehydrogenase in the development and progression of diabetic retinopathy. Diabetes 2009;58:227-234.
16. Nishikawa T, Kukidome D, Sonoda K, et al. Impact of mitochondrial ROS production on diabetic vascular complications. Diabetes Res Clin Pract 2007;77:S41-S45. (Pubitemid 47212551)
17. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006;11:1696-1701.
18. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999;40:809-813.
19. Giebel SJ, Menicucci G, McGuire PG, et al. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the bloodretinal barrier. Lab Invest 2005;85:567-607.
20. Jin M, Kashiwagi K, Iizuka Y, et al. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2001;21:28-33.
21. Shiau MY, Tsai ST, Tsai KJ, et al. Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus. Mt Sinai J Med 2006;73:1024-1028.
22. Yang R, Liu H, Williams I, et al. Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. Ann NY Acad Sci 2007;1103:196-201.
23. Kowluru RA, Kanwar M. Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2. Free Rad Biol Med 2009;46:1677-1685.
24. Kowluru V, Kowluru RA. Increased oxidative stress in diabetes regulates activation of a small molecular weight G-protein, H-Ras, in the retina. Mol Vis 2007;13:602-610.
25. Kowluru RA, Kanwar M. Translocation of H-Ras and its implications in the development of diabetic retinopathy. Biochem Biophys Res Commun 2009;387:461-466.
26. Kuo CT, Hsu MJ, Chen BC, et al. Denbinobin induces apoptosis in human lung adenocarcinoma cells via Akt inactivation, Bad activation, and mitochondrial dysfunction. Toxicol Lett 2008;177:48-58.
27. Phaneuf S, Leeuwenburgh C. Cytochrome c release from mitochondria in the aging heart: a possible mechanism for apoptosis with age. Am J Physiol Regul Integr Comp Physiol 2002;282:R423-R430.
28. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Ann Rev Pharmac Toxicol 2007;47:211-242.
29. Zhoua H-Z, Maa X, Graye MO, et al. Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Comm 2007;358:189-195.
30. Langlois S, Tomasso G, Boivin D, et al. Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism. Exp Cell Res 2005;307:452-464.
31. Kwan JA, Schulze CJ, Wang W, et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 2004;18:690-692.
32. Dawson VL, Dawson TM. Deadly conversations: nuclear-mitochondrial cross-talk. J Bioenerg Biomembr 2004;36:287-294.
33. Goto H, Nishikawa T, Sonoda K, et al. Endothelial MnSOD overexpression prevents retinal VEGF expression in diabetic mice. Biochem Biophys Res Commun 2008;15:814-820.
34. Cox MJ, Sood HS, Hunt MJ, et al. Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol 2002;282:H1197-H1205.
35. Lee SJ, Seo KW, Lee WS, et al. 4-Hydroxynonenal enhances MMP-2 production in vascular smooth muscle cells via mitochondrial ROS-mediated activation of the Akt/NF-kappaB signaling pathways. Free Radic Biol Med 2008;45:1487-1492.